Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.30 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18027856 | 0.88 | HRH3 (0.48) | HRH3CCR2KCNH2PDK1CHRM2 | |
| SCHEMBL18027853 | 0.88 | HRH3 (0.48) | HRH3CCR2KCNH2PDK1CHRM2 | |
| SCHEMBL18721176 | 0.88 | HRH3 (0.48) | HRH3CCR2KCNH2PDK1CHRM2 | |
| SCHEMBL16767988 | 0.85 | HRH3 (0.43) | HRH3CCR2KCNH2PDK1CHRM2 | |
| SCHEMBL16369427 | 0.84 | HRH3 (0.47) | HRH3CCR2KCNH2PDK1CHRM2 | |
| SCHEMBL16767983 | 0.84 | HRH3 (0.45) | HRH3CCR2KCNH2PDK1P2RX3 | |
| SCHEMBL26723898 | 0.81 | HRH3 (0.49) | HRH3CCR2KCNH2PDK1P2RX3 | |
| SCHEMBL18827024 | 0.81 | HRH3 (0.48) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL16812143 | 0.80 | HRH3 (0.49) | HRH3CCR2KCNH2PDK1CHRM2 | |
| SCHEMBL13887585 | 0.79 | ACKR3 (0.39) | HRH3PDK1NPC1RAB9ACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340538-B2 | Dihydropyrimidine compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-05-17 | — | — | US | disclosed |
| US-20150152096-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152096-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | DPYD, SLC10A1, HPRT1 | HRH3 1555/4885CCR2 3894/4885KCNH2 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.